Vancomycin-loaded niosomes integrated within pH-sensitive in-situ forming gel for treatment of ocular infections while minimizing drug irritation

Allam, Ayat; El‐Mokhtar, Mohamed A.; Elsabahy, Mahmoud

doi:10.1111/jphp.13106

Cited by 61 publications

(36 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since vancomycin is very effective in eliminating Methicillin-Resistant Staphylococcus Aureus (MRSA) infections, therefore, in vitro and in vivo studies were performed to assess its activity. It was found that the developed formulation enhanced the antibacterial activity up to 180 folds in MRSA- infected rabbits when compared with vancomycin free drug solution which produced its anti-bacterial activity only up to 2.5 folds [ 25 ].…”

Section: Need For Nanomedicine For Ocular Drug Deliverymentioning

confidence: 99%

Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective

Qamar

Qizilbash

Iqubal

et al. 2020

DDF

View full text Add to dashboard Cite

The structure of the eye is very complex in nature which makes it a challenging task for pharmaceutical researchers to deliver the drug at the desired sites via different routes of administration. The development of the nano-based system helped in delivering the drug in the desired concentration. Improvement in penetration property, bioavailability, and residence time has all been achieved by encapsulating drugs into liposomes, dendrimers, solid lipid nanoparticle, nanostructured lipid carrier, nanoemulsion, and nanosuspension. This review puts emphasis on the need for nanomedicine for ocular drug delivery and recent developments in the field of nanomedicine along with recent patents published in the past few years.

show abstract

Section: Need For Nanomedicine For Ocular Drug Deliverymentioning

confidence: 99%

Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective

Qamar

Qizilbash

Iqubal

et al. 2020

DDF

View full text Add to dashboard Cite

show abstract

“…In the last 10 years, in situ gelling formulations loaded with antimicrobial and antifungal compounds, as such or encapsulated in lipid/polymeric NSs, have been developed for the treatment of infections associated to corneal ulcers. For this purpose, different thermo-reversible [ 36 , 37 , 38 , 39 ], ion-sensitive [ 40 , 41 , 42 , 43 ] and/or pH-triggered [ 44 , 45 ] polymers were used, often in association with cellulose derivatives, such as HPMC and MC, as mucoadhesive and viscosity-enhancing agents.…”

Section: Ocular Routementioning

confidence: 99%

Recent Advances in the Development of In Situ Gelling Drug Delivery Systems for Non-Parenteral Administration Routes

et al. 2020

View full text Add to dashboard Cite

In situ gelling drug delivery systems have gained enormous attention over the last decade. They are in a sol-state before administration, and they are capable of forming gels in response to different endogenous stimuli, such as temperature increase, pH change and the presence of ions. Such systems can be administered through different routes, to achieve local or systemic drug delivery and can also be successfully used as vehicles for drug-loaded nano- and microparticles. Natural, synthetic and/or semi-synthetic polymers with in situ gelling behavior can be used alone, or in combination, for the preparation of such systems; the association with mucoadhesive polymers is highly desirable in order to further prolong the residence time at the site of action/absorption. In situ gelling systems include also solid polymeric formulations, generally obtained by freeze-drying, which, after contact with biological fluids, undergo a fast hydration with the formation of a gel able to release the drug loaded in a controlled manner. This review provides an overview of the in situ gelling drug delivery systems developed in the last 10 years for non-parenteral administration routes, such as ocular, nasal, buccal, gastrointestinal, vaginal and intravesical ones, with a special focus on formulation composition, polymer gelation mechanism and in vitro release studies.

show abstract

“…Interestingly, merging both nanocarriers with the in situ gelling systems was also found in a few studies. Allam et al developed a nanosized niosome loaded in the pH-responsive in situ gelling systems to deliver vancomycin in methicillin-resistant Staphylococcus aureus MRSA patients with ocular infection [67]. Vancomycin is an excellent drug in eradicating MRSA infection.…”

Section: Ocular Bacterial Infectionsmentioning

confidence: 99%

“…On the MRSA-infected rabbit model, the niosomal in situ gel demonstrated a 2.5-fold reduction in the colony-forming unit (CFU) compared with vancomycin solution. The author clarified that the improvement may be due to the interaction between the niosome and the microorganism [67]. The entrapment of niosome in the gel matrix provided a longer contact time for the niosome to fuse with the bacterial cell wall.…”

Section: Ocular Bacterial Infectionsmentioning

confidence: 99%

Potential of Stimuli-Responsive In Situ Gel System for Sustained Ocular Drug Delivery: Recent Progress and Contemporary Research

et al. 2021

View full text Add to dashboard Cite

Eyesight is one of the most well-deserved blessings, amid all the five senses in the human body. It captures the raw signals from the outside world to create detailed visual images, granting the ability to witness and gain knowledge about the world. Eyes are exposed directly to the external environment; they are susceptible to the vicissitudes of diseases. The World Health Organization has predicted that the number of individuals affected by eye diseases will rise enormously in the next decades. However, the physical barriers of the eyes and the problems associated with conventional ocular formulations are significant challenges in ophthalmic drug development. This has generated the demand for a sustained ocular drug delivery system, which serves to deliver effective drug concentration at a reduced frequency for consistent therapeutic effect and better patient treatment adherence. Recent advancement in pharmaceutical dosage design has demonstrated that a stimuli-responsive in situ gel system exhibits the favorable characteristics for providing sustained ocular drug delivery and enhanced ocular bioavailability. Stimuli-responsive in situ gels undergo a phase transition (solution–gelation) in response to the ocular environmental temperature, pH, and ions. These stimuli transform the formulation into a gel at the cul de sac to overcome the shortcomings of conventional eye drops, such as rapid nasolacrimal drainage and short contact time with the ocular surface This review highlights the recent successful research outcomes of stimuli-responsive in situ gelling systems in treating in vivo models with glaucoma and various ocular infections. Additionally, it also presents the mechanism, recent development, and safety considerations of stimuli-sensitive in situ gel as the potential sustained ocular delivery system for treating common eye disorders.

show abstract

Vancomycin-loaded niosomes integrated within pH-sensitive in-situ forming gel for treatment of ocular infections while minimizing drug irritation

Cited by 61 publications

References 41 publications

Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective

Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective

Recent Advances in the Development of In Situ Gelling Drug Delivery Systems for Non-Parenteral Administration Routes

Potential of Stimuli-Responsive In Situ Gel System for Sustained Ocular Drug Delivery: Recent Progress and Contemporary Research

Contact Info

Product

Resources

About